Abstract | OBJECTIVES: Evaluate the reduction in migraine-associated symptoms after administration of a single oral dose of almotriptan. METHODS: This pooled analysis (N=1773) used data from three randomized, placebo-controlled, phase III trials (studies A, B, and C) to determine the incidence of migraine-associated symptoms (defined as nausea, vomiting, photophobia, and phonophobia) 2 hours after a single oral dose of study medication ( almotriptan, sumatriptan, or placebo). Outcome data was extracted from studies A and B for placebo and the almotriptan 6.25-mg and 12.5-mg groups, and from study C for placebo, almotriptan 12.5-mg, and sumatriptan 100-mg groups. RESULTS: CONCLUSION:
|
Authors | Roger Cady |
Journal | Headache
(Headache)
Vol. 42 Suppl 1
Pg. 26-31
(Jan 2002)
ISSN: 1526-4610 [Electronic] United States |
PMID | 11966861
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Serotonin Receptor Agonists
- Tryptamines
- almotriptan
- Sumatriptan
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aged
- Clinical Trials, Phase III as Topic
- Female
- Humans
- Male
- Middle Aged
- Migraine Disorders
(complications, drug therapy)
- Nausea
(drug therapy, etiology)
- Photophobia
(drug therapy, etiology)
- Randomized Controlled Trials as Topic
- Serotonin Receptor Agonists
(administration & dosage, pharmacology, therapeutic use)
- Sumatriptan
(administration & dosage, pharmacology, therapeutic use)
- Treatment Outcome
- Tryptamines
(administration & dosage, pharmacology, therapeutic use)
- Vomiting
(drug therapy, etiology)
|